The Leyden Labs team participated in HERA's recent Implementation Dialogue on July 3 in Brussels. In this dialogue, Commissioner Hadja Lahbib actively listened to a set of diverse stakeholders, who can each help prepare the EU for the next health crisis in various ways. As one of the few biotechnology companies represented, Leyden Labs CFO Marieke van der Lans discussed priorities for improving the development and availability of medical countermeasures, including a focus on the right investment mechanisms, an openness to novel medical countermeasures, and the value of continuous collaboration with regulators.